Topic: psilocybin

Scientific American's Science Quickly examines an early pilot trial of psilocybin-assisted therapy for people with long-term anorexia. The episode carefully discusses reported changes in symptoms and motivation, possible neuroplasticity mechanisms, the small uncontrolled sample and the need for larger randomized studies and clinical safeguards.

Psychedelics like psilocybin have shown rapid and long-lasting efficacy on depressive and anxiety symptoms. Other psychedelics with shorter half-lives, such as DMT and 5-MeO-DMT, have also shown promising preliminary outcomes in major depression, making them interesting candidates for clinical practice. Despite several promising clinical studies, the influence of the context on therapeutic responses or adverse effects remains poorly documented. To address this, we conducted preclinical studies evaluating the psychopharmacological profile of 5-MeO-DMT in contexts previously validated in mice as

The study of altered states of consciousness has long had the potential to provide important insight into the nature of consciousness. In recent years there has been a resurgence of research and public interest in atypical or altered states of consciousness. These have focused both on conditions in which consciousness is considered to be impaired due to brain trauma or enhanced in some way through mediation practices or ingestion of psychedelics. The talk will begin with a brief overview of recent scientific approaches to understanding these different types of altered consciousness. The remain